DekaBank Deutsche Girozentrale’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-24,000
| Closed | -$344K | – | 1359 |
|
|
2025
Q4 | $344K | Hold |
24,000
| – | – | ﹤0.01% | 1062 |
|
|
2025
Q3 | $341K | Hold |
24,000
| – | – | ﹤0.01% | 1050 |
|
|
2025
Q2 | $343K | Sell |
24,000
-2,690
| -10% | -$15.3K | ﹤0.01% | 1039 |
|
|
2025
Q1 | $360K | Buy |
26,690
+2,690
| +11% | +$18K | ﹤0.01% | 1019 |
|
|
2024
Q4 | $300K | Hold |
24,000
| – | – | ﹤0.01% | 1087 |
|
|
2024
Q3 | $317K | Hold |
24,000
| – | – | ﹤0.01% | 1089 |
|
|
2024
Q2 | $317K | Sell |
24,000
-2,690
| -10% | -$16.9K | ﹤0.01% | 1080 |
|
|
2024
Q1 | $360K | Hold |
26,690
| – | – | ﹤0.01% | 1060 |
|
|
2023
Q4 | $370K | Sell |
26,690
-23,310
| -47% | -$289K | ﹤0.01% | 1099 |
|
|
2023
Q3 | $648K | Hold |
50,000
| – | – | ﹤0.01% | 961 |
|
|
2023
Q2 | $938K | Buy |
50,000
+27,000
| +117% | +$450K | ﹤0.01% | 901 |
|
|
2023
Q1 | $329K | Hold |
23,000
| – | – | ﹤0.01% | 1106 |
|
|
2022
Q4 | $433K | Hold |
23,000
| – | – | ﹤0.01% | 1068 |
|
|
2022
Q3 | $795K | Buy |
+23,000
| New | +$734K | ﹤0.01% | 934 |
|
|
2022
Q1 | – | Sell |
-18,000
| Closed | -$647K | – | 1444 |
|
|
2021
Q4 | $647K | Buy |
+18,000
| New | +$756K | ﹤0.01% | 1038 |
|
DekaBank Deutsche Girozentrale's VERV Position: Q1 2026 in Review
DekaBank Deutsche Girozentrale sold out of Verve Therapeutics (VERV) in Q1 2026, closing a stake of 24,000 shares — an estimated $344K sold.
DekaBank Deutsche Girozentrale first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $938K in Q2 2023. 0 funds tracked by Wall St. Rank hold VERV as of Q1 2026.
- DekaBank Deutsche Girozentrale reported no remaining Verve Therapeutics position as of Q1 2026 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 24,000 Verve Therapeutics shares in Q1 2026, an estimated $344K.
- DekaBank Deutsche Girozentrale first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
- DekaBank Deutsche Girozentrale's Verve Therapeutics position peaked at $938K in Q2 2023.
- 0 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2026.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.